These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 33349926)

  • 1. Sodium-glucose cotransporter type 2 inhibitors: managing the small but critical risk of diabetic ketoacidosis.
    Meyer EJ; Thiruvenkatarajan V; Jesudason D
    Med J Aust; 2021 Feb; 214(2):93-93.e1. PubMed ID: 33349926
    [No Abstract]   [Full Text] [Related]  

  • 2. Sodium-glucose cotransporter type 2 inhibitors: managing the small but critical risk of diabetic ketoacidosis.
    Hamblin PS; Wong R; Bach LA
    Med J Aust; 2021 Feb; 214(2):94-94.e1. PubMed ID: 33349919
    [No Abstract]   [Full Text] [Related]  

  • 3. Diabetic ketoacidosis with sodium-glucose cotransporter type 2 inhibitors: a case series.
    McLachlan G; Keith C; Frauman A
    Med J Aust; 2019 Sep; 211(5):237-237.e1. PubMed ID: 31420875
    [No Abstract]   [Full Text] [Related]  

  • 4. In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors.
    Liakos A; Tsapas A; Bekiari E
    Ann Intern Med; 2020 Dec; 173(12):JC70. PubMed ID: 33316195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-glucose cotransporter type 2 inhibitors: managing the small but critical risk of diabetic ketoacidosis.
    Hamblin PS; Wong R; Bach LA
    Med J Aust; 2020 Apr; 212(7):294-296.e1. PubMed ID: 32124975
    [No Abstract]   [Full Text] [Related]  

  • 6. Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature.
    Hernandez-Quiles C; Ramirez-Duque N; Acosta-Delgado D
    Curr Diabetes Rev; 2019; 15(4):259-262. PubMed ID: 30047331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Euglycemic diabetic ketoacidosis in type 2 diabetes treated with a sodium-glucose cotransporter-2 inhibitor.
    Jazi M; Porfiris G
    Can Fam Physician; 2016 Sep; 62(9):722-4. PubMed ID: 27629667
    [No Abstract]   [Full Text] [Related]  

  • 8. SGLT2 inhibitors increase risk for diabetic ketoacidosis in type 2 diabetes.
    Griffin TP; Dinneen SF
    Ann Intern Med; 2020 Oct; 173(8):JC40. PubMed ID: 33075260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An atypical hyperosmolar hyperglycemic state and diabetic ketoacidosis induced by sodium-glucose cotransporter-2 inhibitors: A case report.
    Wang CT; Chang CW; Lu YC; Lam HC; Ku SJ; Tseng KB; Kao YH
    J Formos Med Assoc; 2020 Aug; 119(8):1325-1328. PubMed ID: 31813656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium/Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis: An Example of Complementary Evidence for Rare Adverse Events.
    Alkabbani W; Pelletier R; Gamble JM
    Am J Epidemiol; 2021 Aug; 190(8):1572-1581. PubMed ID: 33751032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative euglycemic diabetic ketoacidosis following use of SGLT-2 inhibitors after cardiac surgery.
    Pontes JPJ; de Melo CS; Arantes FBB; de Souza Ramos JTG; Módolo NSP; Navarro E Lima LH
    J Clin Anesth; 2021 Aug; 71():110201. PubMed ID: 33647525
    [No Abstract]   [Full Text] [Related]  

  • 12. Diabetic ketoacidosis with SGLT2 inhibitors.
    Musso G; Saba F; Cassader M; Gambino R
    BMJ; 2020 Nov; 371():m4147. PubMed ID: 33184044
    [No Abstract]   [Full Text] [Related]  

  • 13. Euglycemic Ketoacidosis With Sodium-Glucose Cotransporter-2 Inhibitor.
    Koch RA; Clark RF
    Am J Ther; 2018; 25(5):e590-e591. PubMed ID: 28452848
    [No Abstract]   [Full Text] [Related]  

  • 14. [Severe diabetic ketoacidosis, acute kidney injury and dehydration due to canagliflozin in type 2 diabetes mellitus patient: Atypical clinical presentation].
    Moreno Obregón F; Espino Montoro A; Marín Martín J; León Jiménez D
    Aten Primaria; 2019 Dec; 51(10):664-666. PubMed ID: 31326123
    [No Abstract]   [Full Text] [Related]  

  • 15. Diabetic ketoacidosis in patients under treatment with sodium-glucose cotransporter type 2 inhibitors.
    López Medina JA; Hernández García C; Espíldora Hernández J
    Med Clin (Barc); 2017 Oct; 149(7):311-312. PubMed ID: 28662890
    [No Abstract]   [Full Text] [Related]  

  • 16. Protracted glycosuria after discontinuation of sodium-glucose cotransporter 2 inhibitors: Implications for weekly dosing and extended risk of euglycemic diabetes ketoacidosis.
    Alhassan S; Rudoni M; Alfonso-Jaume MA; Jaume JC
    J Diabetes; 2019 May; 11(5):410-411. PubMed ID: 30552748
    [No Abstract]   [Full Text] [Related]  

  • 17. Two alcoholic liver cirrhosis patients developed diabetic ketoacidosis after SGLT2 inhibitors-prescription.
    Chao HY; Kornelius E
    J Formos Med Assoc; 2020 Dec; 119(12):1886-1887. PubMed ID: 32690358
    [No Abstract]   [Full Text] [Related]  

  • 18. New insights into cellular links between sodium-glucose cotransporter-2 inhibitors and ketogenesis.
    Yaribeygi H; Maleki M; Butler AE; Jamialahmadi T; Sahebkar A
    J Cell Biochem; 2022 Dec; 123(12):1879-1890. PubMed ID: 36153819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Euglycemic diabetic ketoacidosis associated with the use of a sodium-glucose cotransporter-2 inhibitor.
    Zhang L; Tamilia M
    CMAJ; 2018 Jun; 190(25):E766-E768. PubMed ID: 29941433
    [No Abstract]   [Full Text] [Related]  

  • 20. Sodium-glucose cotransporter-2-induced euglycemic diabetic ketoacidosis unmasks latent autoimmune diabetes in a patient misdiagnosed with type 2 diabetes mellitus: a case report.
    Vadasz B; Arazi M; Shukha Y; Koren O; Taher R
    J Med Case Rep; 2021 Feb; 15(1):62. PubMed ID: 33581735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.